
View larger version (43K):
[in this window]
[in a new window]
|
Fig. 4. Exogenous TGFβ rescues the defective myofibroblast differentiation of Lkb1–/– MEFs. (A) Immunofluorescence staining for SMA of semiconfluent control and Lkb1–/– MEFs following serum starvation (0.2% FCS), as well as subsequent treatment with TGFβ, demonstrating a rescue of SMA staining upon TGFβ treatment. (B) Lysates from non-treated and TGFβ-stimulated control (indicated by `C') and Lkb1–/– MEFs were analyzed by western blotting with antibodies specific for SMA, SM22 or CDK7 (a loading control). Lanes have been reorganized, as indicated by the black bar. (C) Immunofluorescence staining for vinculin (green) and phalloidin (red) of control and Lkb1–/– MEFs, demonstrating recovery of mature focal adhesions and stress fibers in TGFβ-treated Lkb1–/– MEFs. (D) SMA-luc activity following 20 hours of TGFβRI inhibitor (SB431542) treatment, 48 hours after Smad7 transfection or upon deletion of one (Lkb1+/–) or both (Lkb1–/–) alleles of Lkb1. DMSO-treated (left), vector-transfected or control-infected samples are shown with white bars. Fold induction is indicated relative to these controls. Bars represent the average out of three experiments using triplicate samples, except for the Lkb1+/– and Lkb1–/– bars, which represent averages of nine and four experiments, respectively. Error bars indicate s.d.; *P<0.05, **P<0.01, ***P<0.001. (E) SMA-luc and SM22-luc activity in control or Lkb1–/– (AdCre) MEFs with added TGFβ as indicated. Fold induction of corrected luciferase values of non-treated and TGFβ-treated Lkb1–/– MEFs to non-treated control samples are shown. Bars represent averages from three experiments using triplicate samples. Error bars indicate s.d.; *P<0.05, ***P<0.001.
|